

Circulating Long Noncoding RNA Signatures Associate with Incident Diabetes in Older Adults: A Prospective Analysis from the VITA Cohort Study

[Florian A Wenzl](#)¹, [Alessandro Mengozzi](#)^{2,3,4}, [Shafeeq A Mohammed](#)², [Nicola Riccardo Pugliese](#)³, [Alessia Mongelli](#)², [Era Gorica](#)², [Samuele Ambrosini](#)², [Peter Riederer](#)⁵, [Peter Fischer](#)⁶, [Margareta Hinterberger](#)⁶, [Yustina Puspitasari](#)¹, [Thomas F Lüscher](#)^{1,7}, [Giovanni G Camici](#)^{1,8}, [Christian M Matter](#)^{2,9}, [Gian Paolo Fadini](#)¹⁰, [Agostino Virdis](#)³, [Stefano Masi](#)^{3,11}, [Frank Ruschitzka](#)^{2,9}, [Edna Grünblatt](#)^{12,13,14}, [Francesco Paneni](#)^{2,8,9}, [Sarah Costantino](#)^{2,9}

¹ Center for Molecular Cardiology, University of Zurich, Zurich, Switzerland

² Center for Translational and Experimental Cardiology (CTEC), Department of Cardiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland

³ Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

⁴ Scuola Superiore Sant'Anna, Pisa, Italy

⁵ Center of Mental Health, Department of Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Würzburg, Würzburg, Germany

⁶ Department of Psychiatry, Medical Research Society Vienna D.C., Danube Hospital Vienna, Vienna, Austria

⁷ Royal Brompton and Harefield Hospitals and Imperial College, London, U.K.

⁸ Department of Research and Education, University Hospital Zurich, Zurich, Switzerland

⁹ University Heart Center, Cardiology, University Hospital Zurich, Zurich, Switzerland

¹⁰ University of Padua, Department of Medicine, Padua, Italy

¹¹ Institute of Cardiovascular Science, University College London, London, U.K.

¹² Department of Child and Adolescent Psychiatry and Psychotherapy, Psychiatric University Hospital Zurich, University of Zurich, Zurich, Switzerland

¹³ Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland

¹⁴ Neuroscience Center Zurich, University of Zurich and ETH, Zurich, Switzerland

Corresponding authors: Sarah Costantino, sarah.costantino@uzh.ch, and Francesco Paneni, francesco.paneni@uzh.ch

Abstract

OBJECTIVE

Long noncoding RNAs (lncRNAs) are involved in diabetogenesis in experimental models, yet their role in humans is unclear. We investigated whether circulating lncRNAs associate with incident type 2 diabetes in older adults.

RESEARCH DESIGN AND METHODS

A preselected panel of lncRNAs was measured in serum of individuals without diabetes ($n = 296$) from the Vienna Transdanube Aging study, a prospective community-based cohort study. Participants were followed up over 7.5 years. A second cohort of individuals with and without type 2 diabetes ($n = 90$) was used to validate our findings.


RESULTS

Four lncRNAs (ANRIL, MIAT, RNCR3, and PLUTO) were associated with incident type 2 diabetes and linked to hemoglobin A_{1c} trajectories throughout the 7.5-year follow-up. Similar results (for MIAT and PLUTO also in combined analysis) were obtained in the validation cohort.

CONCLUSIONS

We found a set of circulating lncRNAs that independently portends incident type 2 diabetes in older adults years before disease onset.

Graphical Abstract



Introduction

Over the past few decades, the number of older adults with type 2 diabetes has markedly increased and now accounts for almost half of the affected individuals (1). Importantly, the high rate of chronic diabetic complications in newly diagnosed patients calls for early detection and highlights the need for accurate predictors of disease onset to tailor primary prevention efforts (2,3). Long noncoding RNAs (lncRNAs) are epigenetic regulators of gene expression, pre-messenger RNA splicing, RNA translation, and RNA stability, which have been found casually implicated in β -cell dysfunction and insulin resistance in preclinical models (4–6). However, their implication in diabetes development in healthy individuals is largely unknown. In the current study, we aimed to assess the relationship between circulating lncRNAs that are biologically linked to impaired glucose control and incident type 2 diabetes in older adults.

Research Design and Methods

A detailed description of the methodology is provided in the Supplementary Material. In the prospective community-based Vienna Transdanube Aging (VITA) cohort study (7,8), individuals of predominantly European descent aged 75 years at baseline were recruited based on the area of their residence (21st and 22nd districts of Vienna, Austria) (Supplementary Fig. 1). Exclusion criteria were a history of type 2 diabetes or type 1 diabetes or a hemoglobin A_{1c} (HbA_{1c}) concentration $\geq 6.5\%$ (48 mmol/mol) (Supplementary Fig. 2). A total of 296 subjects without diabetes were included and assessed for incident type 2 diabetes at 2.5-, 5-, and 7.5-year follow-up visits. An independent study cohort from the Pisa University Hospital, Italy (9,10), including subjects with ($n = 45$) and without ($n = 45$) type 2 diabetes according to American Diabetes Association criteria (11) was used for a cross-sectional validation of our findings. The primary study end point was the development of type 2 diabetes within 7.5 years (VITA cohort) and the presence of type 2 diabetes at presentation (Pisa cohort).

Profiling of lncRNAs was performed in serum samples collected at study start using a custom PCR array on Quant Studio 5 and 7 cyclers. A systematic literature search identified 15 lncRNAs with disease-specific differential expression and biological links to diabetes, which were included in the array (Supplementary Table 1). Four of these lncRNAs that were 1) differentially detected in individuals with type 2 diabetes, 2) present at levels conclusive with the literature (4,5,12), and 3) correlated with at least one parameter of glucose control (i.e., fasting plasma glucose [FPG] or HbA_{1c}) were included in the final analyses: antisense noncoding RNA in the INK4 locus (ANRIL), retinal noncoding RNA 3 (RNCR3), myocardial infarction associated transcript (MIAT), and PDX1 associated lncRNA upregulator of transcription (PLUTO) (Fig. 1).

Comparisons of lncRNA levels were corrected for multiple testing by the Benjamini-Hochberg procedure. Odds ratios (ORs) for type 2 diabetes with 95% CIs were estimated using binary logistic regression. First, each lncRNA was examined separately in univariable analysis and in multivariable analysis adjusted for traditional risk factors and for the Cambridge Diabetes Risk Score (CDRS) (13) using Bonferroni correction. Two-way interactions for sex and each lncRNA were explored to evaluate potential sex differences in the association of each lncRNA with diabetes. Second, all variables included in univariable analyses were analyzed in a single multivariable regression model using stepwise backward selection. We used resampling techniques to internally validate the results in both cohorts.




Figure 1. Altered lncRNA profile is linked to impaired glycemic status in older adults. **A:** Box-and-whiskers plots of ANRIL, RNCR3, MIAT, and PLUTO in study participants of the VITA cohort with and without incident type 2 diabetes (T2D) during the 7.5-year follow-up period. Data were compared by the Mann-Whitney *U* test. **B:** Correlation matrix showing the strength of correlation between baseline variables of the study participants in the VITA cohort. ANRIL, MIAT, RNCR3, and PLUTO are correlated with each other as well as with HbA_{1c} and FPG. C; cholesterol; CRP, C-reactive protein; **P* < 0.05.

Results

Baseline characteristics of the study population are presented in Table 1 and Supplementary Table 2. In individuals who developed type 2 diabetes, detected levels of ANRIL, RNCR3, and MIAT were significantly higher, while those of PLUTO were significantly lower (Fig. 1A, each $P < 0.001$). In line, ANRIL, MIAT, and RNCR3 positively correlated with HbA_{1c} and FPG at baseline (Fig. 1B), while PLUTO displayed a negative correlation. The levels of all four lncRNAs showed a significant correlation with each other.

Table 1. Baseline characteristics of patients of the VITA cohort

	Whole cohort (n = 296)	Incident type 2 diabetes (n = 37)	No type 2 diabetes (n = 259)	P value
Age, years	75.7 (75.3–76.1)	75.9 (75.5–76.1)	75.6 (75.3–76.1)	0.191
Female, n (%)	181 (61.1)	19 (51.4)	162 (62.5)	0.191
BMI, kg/m ²	26.6 (24.7–29.1)	27.5 (25.6–30.4)	26.6 (24.3–28.8)	0.013
Systolic blood pressure, mmHg	140 (130–150)	140 (128–150)	140 (130–150)	0.843
Diastolic blood pressure, mmHg	80 (70–85)	80 (70–90)	80 (70–85)	0.430
Heart rate, bpm	71 (65–76)	72 (65–78)	70 (65–76)	0.810
Current smoker, n (%)	31 (10.5)	2 (5.4)	29 (11.2)	0.282
History of hypertension, n (%)	191 (64.5)	26 (70.3)	165 (63.7)	0.435
History of stroke, n (%)	24 (8.1)	3 (8.1)	21 (8.1)	1.000
History of CAD, n (%)	77 (26.0)	10 (27.0)	67 (25.9)	0.881
History of PAD, n (%)	38 (12.8)	6 (16.2)	32 (12.4)	0.511
FPG, mmol/L	5.6 (5.2–6.0)	6.2 (5.6–6.8)	5.6 (5.2–5.9)	<0.001
HbA _{1c} , %	5.5 (5.3–5.8)	6.0 (5.8–6.2)	5.5 (5.2–5.8)	<0.001
HbA _{1c} , mmol/mol	37 (34–40)	42 (40–44)	37 (33–40)	<0.001
Triglyceride, mmol/L	1.3 (1.0–1.8)	1.3 (1.0–2.0)	1.3 (1.0–1.8)	0.333
Total C, mmol/L	6.1 (5.2–6.8)	5.8 (5.1–6.3)	6.2 (5.2–6.9)	0.094
LDL C, mmol/L	3.8 (3.1–4.5)	3.7 (3.0–4.2)	3.8 (3.1–4.6)	0.235
HDL C, mmol/L	1.5 (1.2–1.8)	1.3 (1.1–1.5)	1.5 (1.3–1.8)	0.005
Cobalamin, pg/mL	444 (342–647)	453 (304–576)	442 (343–650)	0.651
Folic acid, ng/mL	8.1 (5.9–11.3)	7.5 (5.8–9.8)	8.2 (5.9–11.5)	0.122
CRP, mg/L	2 (1–5)	3 (1–6)	2 (1–5)	0.294
Creatinine, mg/dL	1.1 (1.0–1.2)	1.1 (1.0–1.2)	1.1 (1.0–1.2)	0.927
ANRIL, %	74.9 (55.3–108.3)	283.1 (205.6–328.7)	70.1 (52.4–92.0)	<0.001
MIAT, %	85.2 (61.8–121.0)	183.0 (149.9–256.8)	78.9 (59.9–105.6)	<0.001

	Whole cohort (n = 296)	Incident type 2 diabetes (n = 37)	No type 2 diabetes (n = 259)	P value
RNCR3, %	79.6 (58.4–110.0)	220.2 (198.6–300.7)	75.0 (55.7–98.5)	<0.001
PLUTO, %	96.1 (70.2–126.1)	36.3 (27.3–57.8)	102.2 (79.1–137.3)	<0.001
Beta-blockers, n (%)	89 (41.0)	12 (42.9)	77 (40.7)	0.832
ACE-inhibitors, n (%)	132 (60.8)	18 (64.3)	114 (60.3)	0.688
Antiplatelet agents, n (%)	102 (34.6)	16 (43.2)	86 (33.3)	0.236
Oral anticoagulants, n (%)	23 (7.8)	5 (13.5)	18 (7.0)	0.165
Calcium channel blockers, n (%)	58 (26.7)	10 (35.7)	48 (25.4)	0.250
Diuretics, n (%)	112 (51.6)	13 (46.4)	99 (52.4)	0.556
Statins, n (%)	54 (18.2)	9 (24.3)	45 (17.4)	0.306

Categorical data are shown as numbers (*n*) and percentages (%). Continuous data are presented as median and interquartile range. Groups were compared by χ^2 test, Fisher exact test, and Mann-Whitney *U* test as appropriate. C, cholesterol; CAD, coronary artery disease; CRP, C-reactive protein; PAD, peripheral artery disease

An incremental increase in HbA_{1c} was detected throughout follow-up (Supplementary Fig. 3). In the VITA cohort, variables significantly associated with incident type 2 diabetes were HbA_{1c}, FPG, BMI, HDL cholesterol, circulating levels of ANRIL (OR, 1.52; 95% CI, 1.27–1.80; *P* < 0.001), MIAT (OR, 1.83; 95% CI, 1.43–2.34; *P* < 0.001), RNCR3 (OR, 1.89; 95% CI, 1.45–2.45; *P* < 0.001), and PLUTO (OR, 0.34; 95% CI, 0.22–0.52; *P* < 0.001) (Supplementary Table 3). After adjustment for established risk factors, the findings remained consistent for ANRIL (adjusted [adj] OR, 1.51; 95% CI, 1.22–1.89; *P* < 0.001), MIAT (adj OR, 1.84; 95% CI, 1.37–2.47; *P* < 0.001), RNCR3 (adj OR, 2.26; 95% CI, 1.33–3.84; *P* < 0.001), and PLUTO (adj OR, 0.29; 95% CI, 0.16–0.54; *P* < 0.001) and were confirmed by internal validation (Fig. 2B and Supplementary Tables 4–8). There was no evidence of a sex-specific difference in the association of either lncRNA or incident type 2 diabetes (all *P*_{interaction} > 0.05). Combined analysis of all four lncRNAs with traditional risk factors confirmed RNCR3 and PLUTO as independent risk factors of type 2 diabetes (Table 2). We performed an exploratory analysis to investigate the relationship between the lncRNA profile at baseline and HbA_{1c} trajectories during the 7.5-year follow-up period (Fig. 2C). ANRIL, MIAT, and RNCR3 were linked to an increase in HbA_{1c} throughout the 7.5-year follow-up period. In contrast, PLUTO negatively correlated with the absolute change in HbA_{1c}.




Figure 2. Development of type 2 diabetes (T2D) and changes in the glucose control profile over the 7.5-year follow-up in the VITA study cohort. **A:** Cumulative number of incident type 2 diabetes cases at 2.5-year, 5-year, and 7.5-year follow-up visits. **B:** Forest plot displaying crude (gray) and multivariable-adjusted (red) ORs for the development of type 2 diabetes at 7.5 years with models adjusted for HbA_{1c}, FPG, BMI, HDL cholesterol, and the CDRS. Dots and squares represent ORs with line lengths indicating corresponding 95% CIs. **C:** Scatterplot showing the correlation of circulating lncRNA levels present in serum and the absolute change in HbA_{1c} during 7.5 years of follow-up. ANRIL, MIAT, RNCR3, and PLUTO levels correlate with increasing HbA_{1c}. Correlation was assessed using Spearman's correlation coefficient.

Table 2. Mutually adjusted ORs for incident type 2 diabetes in the VITA cohort

	Adjusted OR (95% CI) <i>P</i> value	
HbA _{1c} (%) [*]	1.79 (1.03–3.10)	0.040
Total C (mmol/L) [†]	0.95 (0.90–1.01)	0.093
HDL C (mmol/L) [‡]	1.10 (1.00–1.21)	0.062
PLUTO (%) [‡]	0.51 (0.26–0.99)	0.047
RNCR3 (%) [‡]	1.78 (1.16–2.72)	0.008

Data represent the result of a backward selection process with the lncRNAs of interest and traditional risk factors included in the initial model. C, cholesterol.

^{*}Per 0.1% increment.

[†]Per 0.0256 mmol/L increment.

[‡]Per 10% increment.

We validated our findings in an independent cohort of subjects with and without type 2 diabetes (Supplementary Table 9). Patients with type 2 diabetes showed higher levels of ANRIL, MIAT, and RNCR3 and lower levels of PLUTO (each $P < 0.001$) (Supplementary Fig. 4A). Accordingly, ANRIL, MIAT, and RNCR3 positively correlated with FPG and HbA_{1c}, while PLUTO showed a negative correlation (HbA_{1c}: each $P < 0.001$; FPG: $P < 0.001$ for MIAT, RNCR3, and PLUTO, and $P = 0.007$ for ANRIL) (Supplementary Fig. 4B and C). All lncRNAs were associated with type 2 diabetes in univariable and multivariable analyses (Supplementary Tables 10–12).

Conclusions

Here, we report for the first time that a set of circulating lncRNAs (ANRIL, MIAT, RNCR3, and PLUTO) associate with the development of type 2 diabetes in a prospective cohort of 296 older adults over a 7.5-year follow-up. Remarkably, these findings were confirmed in an external cohort (Supplementary Fig. 5). Furthermore, the identified set of lncRNAs was found to correlate with both baseline and follow-up HbA_{1c} levels.

Very few studies have assessed circulating lncRNAs in human subjects with type 2 diabetes (14–16). While a small number of cross-sectional and short-term longitudinal reports showed higher expression levels of ANRIL (14,15) and MIAT (14–16) in the circulation of patients with advanced type 2 diabetes, previous work focused on the relationship of lncRNAs to established disease rather than future diabetes onset. The association between circulating lncRNAs and incident diabetes has important implications. First, their predictive potential and the wide availability of quantitative PCR devices might have relevance for risk stratification and disease prevention (17). Second, our results in humans support the notion that disease-specific epigenetic dysregulation precedes diabetes onset (18). Third, our study paves the way for mechanistic investigations of the identified lncRNAs in diabetes development and progression.

The link between lncRNA levels and impaired glycemic status is supported by their correlation with both 1) baseline FPG and HbA_{1c} and 2) follow-up HbA_{1c} values over the 7.5-year follow-up period. Our results suggest that ANRIL, RNCR3, MIAT, and PLUTO are part of a distinct lncRNA signature present several years before the clinical onset of type 2 diabetes and may be causally involved in the progressive loss of glucose homeostasis. Matching our results, PLUTO was found to be downregulated in pancreatic islets of patients with type 2 diabetes, where it modulates β -cell-specific transcriptional networks (12). However, in view of mechanistic evidence for a reciprocal modulation of lncRNAs and glucose levels (5,6,12,19,20), observational results from the current study need careful interpretation.

Our study has some limitations. First, it is limited by a relatively small sample size, yet benefits from its community-based study design with unique long-term follow-up data. Second, waist circumference and physical activity status were not available. Yet, our multivariable models were controlled for established confounders, including the CDRS, a validated diabetes risk assessment tool (13). Third, our literature search included primarily preclinical studies, given the limited evidence in humans. This may have affected the lncRNA selection. Fourth, given that no oral glucose tolerance test was performed, we cannot exclude the possibility that the selection criteria may have led to the inclusion of a small number of individuals with undetected preexisting diabetes. Finally, our study sample reflects a specific subgroup of the general population, and selection bias cannot be excluded with certainty. Caution is required when extrapolating the results to other age-groups and ethnicities.

Our proof-of-concept study shows for the first time that a set of lncRNAs is independently related to trajectories of impaired glucose control and future development of type 2 diabetes on top of HbA_{1c}, FPG, BMI, and other established risk factors. Given the broad availability of quantitative PCR devices, our findings could have important clinical applications. Proactive approaches to risk stratification and early diabetes detection may improve patient outcomes and mitigate the socio-sanitary burden.

Article Information

Funding. F.A.W. is supported by the Lindenhof Foundation. A.Me. is the recipient of an International Grant from the Italian Society of Arterial Hypertension. S.A.M. and S.A. are the recipients of a Forschungskredit Candoc grant from the University of Zurich. P.R., P.F., M.H., and E.Gr. conducted the VITA study under the support of the Ludwig Boltzmann Institute of Aging Research Vienna, Austria. C.M.M. is funded by the Swiss National Science Foundation and the Swiss Heart Foundation. F.P. is the recipient of an H.H. Sheikh Khalifa bin Hamad Al Thani Foundation Assistant Professorship at the Faculty of Medicine, University of Zurich. This work was supported by the Swiss National Science Foundation (no. 310030_197557), the Swiss Heart Foundation (no. FF19045), the Stiftung für wissenschaftliche Forschung, the Olga Mayenfisch Foundation, the Swiss Life Foundation, the Kurt und Senta-Hermann Stiftung, the EMDO Stiftung and the Schweizerische Diabetes-Stiftung (to F.P.), the Holcim Foundation, the Swiss Heart Foundation, and the Swiss Life Foundation and the Gebauer Stiftung (to S.C.).

Duality of Interest. G.G.C. is coinventor on the International Patent WO/2020/226993 filed in April 2020. The patent relates to the use of antibodies which specifically bind IL-1 α to reduce various sequelae of ischemia-reperfusion injury to the central nervous system. G.G.C. is a consultant to Sovid Solutions Limited. T.F.L. has, outside this work, received research and educational grants and in part honoraria from Abbott, Amgen, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo,

Novartis, Sanofi, Servier, and CSL Vifor. C.M.M. has received research grants to the institution from Eli Lilly, AstraZeneca, Roche, Amgen, Novartis, Novo Nordisk, and MSD, including speaker or consultant fees. F.R. has not received personal payments from pharmaceutical companies or device manufacturers in the last three years (remuneration for the time spent in activities, such as participation as steering committee member of clinical trials and member of the Pfizer Research Award selection committee in Switzerland, were made directly to the University of Zurich). The Department of Cardiology (University Hospital of Zurich/University of Zurich) reports research, educational, and/or travel grants from Abbott, Amgen, AstraZeneca, Bayer, Berlin Heart, B. Braun, Biosense Webster, Biosensors Europe AG, Biotronik, Bristol Myers Squibb, Boehringer Ingelheim, Boston Scientific, Bracco, Cardinal Health Switzerland, Corteria, Daiichi Sankyo, Diatools AG, Edwards Lifesciences, Guidant Europe NV (BS), Hamilton Health Sciences, Kaneka Corporation, Kantar, Labormedizinisches Zentrum, Medtronic, MSD, Mundipharma Medical Company, Novartis, Novo Nordisk, Orion, Pfizer, Quintiles Switzerland Sarl, Sahajanand IN, Sanofi, Sarstedt AG, Servier, SIS Medical, SSS International Clinical Research, Terumo Deutschland, Trama Solutions, V-Wave, Vascular Medical, Vifor, Wissen.Plus, and ZOLL. The research and educational grants do not impact F.R.'s personal remuneration. No other potential conflicts of interest relevant to this article were reported.

Author Contributions. F.P. and S.C. conceived the study. F.A.W., A.Me., F.P., and S.C. performed statistical analyses. S.A.M., A.Mo., E.Go., S.A., Y.P., and S.C. performed RNA measurements and generated the data. A.Me., N.R.P., P.R., P.F., M.H., G.P.F., A.V., S.M., F.R., and E.Gr. contributed to the project logistics. N.R.P., E.Go., P.R., P.F., M.H., T.F.L., G.G.C., C.M.M., G.P.F., A.V., S.M., F.R., and E.Gr. provided critical intellectual feedback during manuscript preparation. F.A.W. drafted the initial version of the manuscript. F.A.W., A.Me., F.P., and S.C. wrote the manuscript. All authors critically revised the manuscript and approved the final version. S.C. and F.P. are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Footnotes

This article contains supplementary material online at <https://doi.org/10.2337/figshare.22350793>.

F.A.W., A.M., S.A.M., and N.R.P. contributed equally to this work.

F.P. and S.C. jointly directed the study.

References

1. Bellary S, Kyrou I, Brown JE, Bailey CJ. Type 2 diabetes mellitus in older adults: clinical considerations and management. *Nat Rev Endocrinol* 2021;17:534–548 [DOI: 10.1038/s41574-021-00512-2]
2. Ahmad E, Lim S, Lamptey R, Webb DR, Davies MJ. Type 2 diabetes. *Lancet* 2022;400:1803–1820 [DOI: 10.1016/S0140-6736(22)01655-5]
3. Kirkman MS, Briscoe VJ, Clark N, et al. Diabetes in older adults. *Diabetes Care* 2012;35:2650–2664 [DOI: 10.2337/dc12-1801]
4. Dieter C, Lemos NE, Corrêa NRF, Assmann TS, Crispim D. The Impact of lncRNAs in diabetes mellitus: a systematic review and in silico analyses. *Front Endocrinol (Lausanne)* 2021;12:602597. [DOI: 10.3389/fendo.2021.602597]
5. Statello L, Guo CJ, Chen LL, Huarte M. Gene regulation by long non-coding RNAs and its biological functions. *Nat Rev Mol Cell Biol* 2021;22:96–118 [DOI: 10.1038/s41580-020-00315-9]

6. López-Noriega L, Rutter GA. Long non-coding RNAs as key modulators of pancreatic β -cell mass and function. *Front Endocrinol (Lausanne)* 2021;11:610213. [DOI: 10.3389/fendo.2020.610213]
7. Fischer P, Jungwirth S, Krampla W, et al. Vienna Transdanube Aging “VITA”: study design, recruitment strategies and level of participation. *J Neural Transm Suppl* 2002;105–116 [DOI: 10.1007/978-3-7091-6139-5_11]
8. Jungwirth S, Zehetmayer S, Bauer P, Weissgram S, Tragl KH, Fischer P. Screening for Alzheimer’s dementia at age 78 with short psychometric instruments. *Int Psychogeriatr* 2009;21:548–559 [DOI: 10.1017/S1041610209008904]
9. Pugliese NR, Paneni F, Mazzola M, et al. Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure. *Eur J Heart Fail* 2021;23:1858–1871 [DOI: 10.1002/ehf.2337]
10. Pugliese NR, Balletti A, Armenia S, et al. Ventricular-arterial coupling derived from proximal aortic stiffness and aerobic capacity across the heart failure spectrum. *JACC Cardiovasc Imaging* 2022;15:1545–1559 [DOI: 10.1016/j.jcmg.2022.03.024]
11. American Diabetes Association . 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes-2020. *Diabetes Care* 2020;43(Suppl. 1):S14–S31 [DOI: 10.2337/dc20-S002]
12. Akerman I, Tu Z, Beucher A, et al. Human pancreatic β cell lncRNAs control cell-specific regulatory networks. *Cell Metab* 2017;25:400–411 [DOI: 10.1016/j.cmet.2016.11.016]
13. Mendez CE, Walker RJ, Dawson AZ, Lu K, Egede LE. Using a diabetes risk score to identify patients without diabetes at risk for new hyperglycemia in the hospital. *Endocr Pract* 2021;27:807–812 [DOI: 10.1016/j.eprac.2021.04.003]
14. Sathishkumar C, Prabu P, Mohan V, Balasubramanyam M. Linking a role of lncRNAs (long non-coding RNAs) with insulin resistance, accelerated senescence, and inflammation in patients with type 2 diabetes. *Hum Genomics* 2018;12:41. [DOI: 10.1186/s40246-018-0173-3]
15. Toraih EA, Abdelghany AA, Abd El Fadeal NM, Al Ageeli E, Fawzy MS. Deciphering the role of circulating lncRNAs: RNCR2, NEAT2, CDKN2B-AS1, and PVT1 and the possible prediction of anti-VEGF treatment outcomes in diabetic retinopathy patients. *Graefes Arch Clin Exp Ophthalmol* 2019;257:1897–1913 [DOI: 10.1007/s00417-019-04409-9]
16. de Gonzalo-Calvo D, Kenneweg F, Bang C, et al. Circulating long-non coding RNAs as biomarkers of left ventricular diastolic function and remodelling in patients with well-controlled type 2 diabetes. *Sci Rep* 2016;6:37354. [DOI: 10.1038/srep37354]
17. Gadd DA, Hillary RF, McCartney DL, et al. Epigenetic scores for the circulating proteome as tools for disease prediction. *eLife* 2022;11:e71802. [DOI: 10.7554/eLife.71802]
18. Dayeh T, Tuomi T, Almgren P, et al. DNA methylation of loci within ABCG1 and PHOSPHO1 in blood DNA is associated with future type 2 diabetes risk. *Epigenetics* 2016;11:482–488 [DOI: 10.1080/15592294.2016.1178418]
19. Cai R, Jiang J. LncRNA ANRIL silencing alleviates high glucose-induced inflammation, oxidative stress, and apoptosis via upregulation of MME in podocytes. *Inflammation* 2020;43:2147–2155 [DOI: 10.1007/s10753-020-01282-1]
20. Yan B, Yao J, Liu JY, et al. lncRNA-MIAT regulates microvascular dysfunction by functioning as a competing endogenous RNA. *Circ Res* 2015;116:1143–1156 [DOI: 10.1161/CIRCRESAHA.116.305510]